Catharina Missailidis
Research Subjects
Research Interests
Catharina Missailidis has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Finn Filén
Department of Infectious Diseases/Venhälsan
2 shared publications - Andreas Jacks
Department of Communicable Disease Prevention and Control Stockholm Region , Stockholm
1 shared publication Anna Mia Ekström
Department of Infectious Diseases/Venhälsan, Södersjukhuset , Stockholm
1 shared publication- Emmi Andersson
Karolinska University Laboratory, Karolinska University Hospital
1 shared publication - Fredrik Månsson
The Department of Translational Medicine, Lund University, Malmö, Sweden
1 shared publication - Jaran Eriksen
Department of Global Public Health, Karolinska Institutet, 17177 Stockholm, Sweden
1 shared publication
Latest Publications
- 25 August 2026
- Published by Taylor & Francis in Infectious Diseases
- Vol. 58 (10) , 1062-1070
HIV pre-exposure prophylaxis (PrEP) – Swedish recommendation for management 2026
Emtricitabine/tenofovir disoproxil fumarate (TDF) is approved in Sweden for use as pre-exposure prophylaxis (PrEP) in adults and adolescents at high risk of HIV infection. International guidelines ...
- 25 August 2026
- Published by Taylor & Francis in Infectious Diseases
- Vol. 58 (10) , 1062-1070
HIV pre-exposure prophylaxis (PrEP) – Swedish recommendation for management 2026
Emtricitabine/tenofovir disoproxil fumarate (TDF) is approved in Sweden for use as pre-exposure prophylaxis (PrEP) in adults and adolescents at high risk of HIV infection. International guidelines ...
- Open Access
- 2 June 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (6) , ofag337
Mpox Disease Severity Reduced in Intradermally MVA-BN Vaccinated Compared to Unvaccinated Patients in Sweden: A Retrospective 2024–2025 Observational Case-series
Background: Modified Vaccinia Ankara–Bavarian Nordic vaccination (MVA-BN) prevents mpox, whether offered subcutaneously or intradermally. Intradermal administration has been implemented as a dose-sparing strategy, but evidence on durability of protection and long-term clinical impact is limited. We evaluated mpox severity over time in a limited number of mpox cases following primary intradermal MVA-BN vaccination. Methods: We conducted a retrospective case series of laboratory-confirmed mpox diagnosed between January 2024 and October 2025 at a major HIV and sexual health center in Stockholm, Sweden. Demographic and clinical data, vaccination history, and treatment outcomes were extracted from medical records. Disease severity was assessed using the validated Mpox Severity Score System. Results: Seventy-nine patients were included (median age, 40 years); 32 unvaccinated and 47 had prior vaccination with smallpox vaccine (n = 6), smallpox plus MVA-BN (n = 11), or MVA-BN only (n = 30). All MVA-BN doses were administered intradermally. Breakthrough infections occurred a median of 22 months after MVA-BN vaccination. Vaccinated individuals had significantly milder disease, with lower median severity score (5.0 vs 8.0; P < .0001), fewer lesions, more limited distribution, and less mucosal involvement. No MVA-BN-vaccinated patient developed complications with bacterial superinfection (P = .002), and analgesic requirements were reduced (P = .004). Disease severity showed a modest inverse correlation with time since vaccination (r = −0.42, P = .01). Similar attenuation was observed in vaccinated individuals with well-controlled HIV. Conclusions: Dose-sparing intradermal MVA-BN vaccination is associated with sustained reduction in mpox severity for up to 3 years. Continued vaccination of high-risk populations is supported, while prospective studies are needed to clarify long-term protection and optimize vaccination strategies.
- 2 June 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (6) , ofag337
Open AccessMpox Disease Severity Reduced in Intradermally MVA-BN Vaccinated Compared to Unvaccinated Patients in Sweden: A Retrospective 2024–2025 Observational Case-series
Background: Modified Vaccinia Ankara–Bavarian Nordic vaccination (MVA-BN) prevents mpox, whether offered subcutaneously or intradermally. Intradermal administration has been implemented as a dose-sparing strategy, but evidence on durability of protection and long-term clinical impact is limited. We evaluated mpox severity over time in a limited number of mpox cases following primary intradermal MVA-BN vaccination. Methods: We conducted a retrospective case series of laboratory-confirmed mpox diagnosed between January 2024 and October 2025 at a major HIV and sexual health center in Stockholm, Sweden. Demographic and clinical data, vaccination history, and treatment outcomes were extracted from medical records. Disease severity was assessed using the validated Mpox Severity Score System. Results: Seventy-nine patients were included (median age, 40 years); 32 unvaccinated and 47 had prior vaccination with smallpox vaccine (n = 6), smallpox plus MVA-BN (n = 11), or MVA-BN only (n = 30). All MVA-BN doses were administered intradermally. Breakthrough infections occurred a median of 22 months after MVA-BN vaccination. Vaccinated individuals had significantly milder disease, with lower median severity score (5.0 vs 8.0; P < .0001), fewer lesions, more limited distribution, and less mucosal involvement. No MVA-BN-vaccinated patient developed complications with bacterial superinfection (P = .002), and analgesic requirements were reduced (P = .004). Disease severity showed a modest inverse correlation with time since vaccination (r = −0.42, P = .01). Similar attenuation was observed in vaccinated individuals with well-controlled HIV. Conclusions: Dose-sparing intradermal MVA-BN vaccination is associated with sustained reduction in mpox severity for up to 3 years. Continued vaccination of high-risk populations is supported, while prospective studies are needed to clarify long-term protection and optimize vaccination strategies.